در این تحقیق ۱۵۹۶ بیمار Lopinavir-Ritonavir دریافت کردهاند و ۳۳۷۶ نفر در گروه کنترل ( درمان متداول به تنهایی) بودهاند.
تفاوت معناداری در دو گروه از لحاظ مرگ و میر در مدت ۲۸ روز و مدت زمان بستری در بیمارستان و نیاز به ونتیلاتور مشاهده نشده است.
A total of 1596 patients were randomised to lopinavir-ritonavir and compared with 3376 patients randomised to usual care alone. Of these patients, 4% required invasive mechanical ventilation when they entered the trial, 70% required oxygen alone, and 26% did not require any respiratory intervention. There was no significant difference in the primary endpoint of 28-day mortality (22.1% lopinavir-ritonavir vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18]; p=0.58) and the results were consistent in different subgroups of patients. There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.
No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in
RECOVERY — RECOVERY Trial
منبع:
https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery